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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S425donors. Many of these proteins are cartilage speciﬁc proteoglycans such
as hyaluronan and proteoglycan link protein 1, aggrecan core protein or
lumican as well as some proteins with a well-known role in the
pathogenesis of OA like COMP or MMP3. On the other hand, 21 proteins
exhibited a signiﬁcantly reduced abundance in OA patients when
compared to controls. Interestingly, we detected several proteins which
belong to the tenascin protein family, like tenascin-X, which accelerates
collagen ﬁbril formation. We also found WISP2 decreased at day 14,
suggesting a lower activity of the Wnt signaling pathway in OA cells.
Conclusions: The identiﬁcation and quantiﬁcation of these secreted
proteins enhance our knowledge on the extracellular regulation of the
chondrogenesis and allow the identiﬁcation of extracellular markers of
this process. Moreover, the lower expression of some of them in OA
patients (like tenascin-X or WISP2), suggest their putative usefulness
for the molecular monitorization of the chondrogenesis in cell therapy-
based approaches for cartilage repair.
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A LIPIDOMIC STUDY OF SPHINGOLIPID SPECIES IN HUMAN
SYNOVIAL FLUID
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Purpose: Articular synovial ﬂuid (SF) is a complex mixture of compo-
nents either derived from plasma or locally synthesized by synovial
tissues, which are involved in nutrition, communication, shock
absorption, and lubrication. Alterations in its composition can be
associated with increased friction, leading to articular cartilage damage,
or with changes in inﬂammatory status of synovial joints. We already
quantiﬁed 130 phospholipid species in human osteoarthritis (OA) and
rheumatoid arthritis (RA) SF. The presented lipidomic investigation
aims to quantify for the ﬁrst time, the composition of sphingolipids
[sphingomyelins (SM), ceramides (Cer), hexosylceramides (HexCer) and
dihexosylceramides (Hex2Cer) species] in the SF of knee joints from
unaffected controls, patients with early (eOA) and late (lOA) stages of
OA and from RA patients, and to further elucidate whether the con-
centrations of individual lipid species are associated with the stage of
OA disease.
Methods: According to predeﬁned inclusion and exclusion criteria
patients were included in the study. The use of human SF for this study
was approved by the local ethics committee of our university, and all
participants provided written informed consent. Lipids were extracted
from SF without cells and cellular debris from 9 postmortem donors
(control), 18 RA, and 30 OA patients. OA group was subcategorized as
early (n ¼ 17) and late (n ¼ 13) using Outerbridge score. RA patients
were classiﬁed according to the criteria of the American College of
Rheumatology. Lipids were quantiﬁed using electrospray ionization
tandem mass spectrometry - directly or coupled with hydrophilic
interaction liquid chromatography. The quantitative values of all lipid
species were corrected by the method described by Kraus et al. (2002).
The Kruskal-Wallis test adjusted with a false discovery rate (FDR) of 10%
and the Wilcoxon rank sum test were applied to determine statistically
signiﬁcant differences. P values < 0.05 were considered to be statisti-
cally signiﬁcant.
Results: We provide a novel, detailed overview of sphingolipid species
in human SF. The analytical set-up used in the present study allowed us
to quantitate 35 different sphingolipid species. We identiﬁed 19 SM
species, based on the length and saturation of the attached fatty acids.
SM 34:1 was the predominant species among SMs. In addition, versus
control SF, all species were elevated in eOA, lOA and RA SF. Remarkably,
all SM species rose approximately 2-fold in SF from eOA to lOA and
approximately 1.5-fold in SF from eOA to RA. However, we found no
signiﬁcant different levels of SM species in lOA compared with RA SF.
Also, 6 Cer, 5 HexCer and 5 Hex2Cer were identiﬁed in human SF. Cer
d18:0/24 was the predominant species. Moreover, most Cer species
contained saturated fatty acids in all cohorts. Compared to control SF,
the levels of most Cer species were 4.5-fold higher in lOA and 5.8-fold in
RA SF. Moreover, all Cer species rose approximately 1.7-fold in SF from
eOA to RA, and nearly 1.3-fold in SF from lOA to RA.
Conclusions: This lipidomic investigation present for the ﬁrst time a
detailed overview of sphingolipid species in human SF. Compared to
control SF the concentrations of sphingolipid species such as SM andCer were found to be elevated in eOA, lOA and RA SF. Since, disease and
stage-dependent differences in the composition and concentrations of
lipid species might result not only in an impaired lubrication but also in
an altered inﬂammatory status of joints, sphingolipids appear to be
associated with the pathogenesis of OA and RA. Our study lays the
foundation for addressing speciﬁc questions regarding the biosynthesis
and function of sphingolipid species in SF.
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Purpose: Osteoarthritis (OA) is characterized by the loss of structural
components from the extracelullar matrix (ECM) of articular cartilage.
The progressive release of proteins from the tissue and an abnormal
metabolic activity can be speciﬁcally detected by the immune system,
leading to a humoral immune response producing immunoglobulins
against these proteins (autoantibodies). Autoantibodies are stable cir-
culating proteins, easily measurable in serum, and may be the signature
before clinical manifestations of the disease. Protein microarrays have
emerged providing a tool for the identiﬁcation of disease immuno-
signatures. The aim of this study was to detect the presence of auto-
antibodies in OA serum samples and compare these results with those
obtained from healthy (CTRL) and rheumatoid arthritis (RA) sera.
Methods: Antibodies were detected using an speciﬁc Nucleic Acid
Protein Programmable Array (NAPPA) designed and constructed as
previously described by Ramachandran et al. 2008, containing 80
sequence-veriﬁed full-length human genes obtained from the Center
for Personalized Diagnostics at the Arizona State University (www.
dnasu.org). Once protein was displayed by in situ protein expression
system, NAPPA arrays were incubated in optimized conditions with 20
OA, 20 RA and 18 CTRL serum samples. The autoantibodies were
detected by anti-human IgG-HRP and ﬂuorescence dye. Array images
were obtained and processed by Genepix4000B and GenePix Software
6.0. For data analysis, background correction was performed by sub-
traction of the ﬁrst quartile of non-DNA spots intensity and then divided
the excess intensity by the median of spots without DNA across arrays.
Results: Signiﬁcantly (p< 0.05) 4 different expression of autoantibodies
against four different proteins has been observed between OA and CTRL
serum samples. Of note, 2 of these proteins are related to the metabo-
lism of ECM; the others are associated to cell adhesion (1) and bone
mineralization (1). Most interestingly, this approach allowed the dif-
ferential classiﬁcation of RA and OA patients by the detection of 3
speciﬁc autoantibodies against proteins involved in cell proliferation
and bone mineralization processes; one of these proteins also dis-
tinguishing between CTRL and RA subjects.
Conclusions: We have identiﬁed the presence of speciﬁc autoanti-
bodies in OA allowing to distinguish between OA and CTRL patients and
most interestingly, between OA and RA patients. These autoantibodies
released to the serum might have a biomarker value to more accurate
early diagnosis and prognosis of OA patients in clinical routine.
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Purpose: The low-molecular-weight subset of the cartilage proteome
(also termed cartilage peptidome) may have a diagnostic potential in
osteoarthritis (OA) research, not yet fully exploited. The aim of this
study is to investigate the cartilage secretome by means of peptidomic
analysis and to provide a novel source for OA biomarker discovery.
Methods: Tissue explants were obtained from the dissection of human
OA cartilages, both from the unwounded zone (UZ) and the wounded
zone (WZ). The study was approved by the local ethical committee.
Cartilage shavings from each zone were cut into 6 mm discs and ﬁve
